Summary
This course will help you understand the principles of pharmacovigilance, including factors such as Adverse Drug Reactions (ADRs), pharmacovigilance legislation and regulations, the methods used to collect and evaluate adverse drug reactions, preferred communication channels when communicating with authorities and the ethical considerations and implications of pharmacovigilance.
You will be introduced to suspected unexpected serious adverse reactions (SUSARs), individual case safety reports (ICSRs), periodic safety update reports (PSUR) and development safety update reports (DSUR), product safety information and signal detection, quality systems and pharmacovigilance audits and inspections.
The course is offered every 2 years.
Keywords
- Pharmacovigilance Legislation
- Safety Data
- Post-Authorization Safety Studies (PASS)
- Risk Management Plans (RMP)
- Pharmacovigilance Evaluation
- Pharmacoepidemiology
- Communication
Hi! Do you need help choosing the right course?
We are ready to help you at +45 39 27 60 60 or contact@atriumcph.com
Course leader(s) & Lecturer(s)
- Mette Stie KallesøeCourse leaderSenior Principal Professional, Deputy QPPV
LEO Pharma A/S - Anette Kirstine StarkCourse leaderMD PHD
Lægemiddelstyrelsen - Karsten LollikeLecturerDirector
Novo Nordisk A/S - Novo Allé - Atheline Major-PedersenLecturerSafety Surveillance Principal Specialist at Global Safety
Novo Nordisk A/S - Maria OxenbøllLecturerPharmacovigilance manager
FERRING PHARMACEUTICALS A/S - Marcus SchartauLecturerSafety Surveillance Risk Management Specialist
NOVO NORDISK A/S
IS THIS COURSE FOR YOU?
Whether you are new to the field or have several years of experience, this programme is relevant if you are a pharmacovigilance professional who wants to improve your knowledge and skills.
What you will learn
- The principles of pharmacovigilance
- How to analyze and evaluate methods and data in drug safety reporting
- How to analyze and evaluate regulations and guidelines in pharmacovigilance
- Best practices in pharmacovigilance working processes when preparing safety assessments and reports
- How to design appropriate pharmacovigilance working methods in a dynamic and changing environment
What your company will get
- A safety and pharmacovigilance professional who understands the principles of pharmacovigilance
- A safety and pharmacovigilance professional that can independently analyze and evaluate methods and data in drug safety reporting
- A safety and pharmacovigilance professional who can analyze and evaluate regulations and guidelines in pharmacovigilance
- An employee who can provide valuable input to all other team members involved in pharmacovigilance working processes
Course calendar
DAY 1
- Overview and introduction to international legislation and organisations
- History and background of pharmacovigilance EU legislative process
- Current EU pharmacovigilance legislation and guidance
- EU Organization: EMA, CHMP, PRAC, CMD(h), National Competent Authorities, Efpia, ICH
DAY 2
- Introduction to pharmacovigilance quality systems, audits and inspections
- Introduction to the Pharmacovigilance Systems Master File
- Introduction to safety in clinical trials • Responsibilities of the Qualified Person for Pharmacovigilance (QPPV)
- Individual Case Safety Reports (ICSRs) and case processing
- Workshop on Individual Case Safety Reports
DAY 3
- Introduction to Periodic Safety Update Reports (PSURs)
- Introduction to safety surveillance
- Introduction to Risk Management Plans (RMP)
- Introduction to pharmacovigilance related studies
- Trends and challenges in pharmacovigilance
Registration
Registration deadline7. Jun 2022
Lersø Parkallé 101
2100 København Ø
Course information
Literature
Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.
Please familiarize yourself with the mandatory readings before starting the course.
The mandatory readings are also part of the examination syllabus.
Prerequisites
To enroll in this course, you must have a relevant educational background at bachelor level and, as a minimum, two years of experience in drug safety or pharmacovigilance, or other equivalent qualifications. We consider all applications upon registration.
If you do not fulfill the requirements, you can still apply for the course if you have suitable experience in the pharmaceutical/biological area that would allow you to benefit from the training and enable you to participate actively during the module. Up to 10% of the positions on our course are filled by applicants who have no or limited experience in drug safety or pharmacovigilance. We consider applicants on a case-by-case basis.
Examination
The exam is held online, usually 4-6 weeks after the course.
You will receive a link with exam questions via your personal Atrium log-in.
In order to participate in the exam, you must have attended the course.
This course is a part of this programme
The demand for qualified pharmacovigilance professionals is high. Become a sought after and highly valued professional by attending our pharmacovigilance training and acquire the Pharmacovigilance Diploma
Read moreCourse leader(s)
LEO Pharma A/S
Lægemiddelstyrelsen
Lecturer(s)
Novo Nordisk A/S - Novo Allé
Novo Nordisk A/S
FERRING PHARMACEUTICALS A/S
NOVO NORDISK A/S
You may also be interested in these courses
WANT TO KNOW MORE or need help?
Contact Client Manager Ida Salicath at +45 39 15 09 46
Send me a message